RBF Capital LLC Buys New Position in Pediatrix Medical Group, Inc. (NYSE:MD)

RBF Capital LLC purchased a new position in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 146,246 shares of the company's stock, valued at approximately $1,695,000. RBF Capital LLC owned approximately 0.17% of Pediatrix Medical Group as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Rubric Capital Management LP boosted its stake in Pediatrix Medical Group by 1.5% during the third quarter. Rubric Capital Management LP now owns 8,275,000 shares of the company's stock worth $95,907,000 after buying an additional 125,000 shares during the last quarter. Dana Investment Advisors Inc. boosted its stake in Pediatrix Medical Group by 80.3% during the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company's stock worth $7,725,000 after buying an additional 455,785 shares during the last quarter. ArrowMark Colorado Holdings LLC boosted its stake in Pediatrix Medical Group by 3.8% during the third quarter. ArrowMark Colorado Holdings LLC now owns 787,649 shares of the company's stock worth $9,129,000 after buying an additional 28,804 shares during the last quarter. Brandes Investment Partners LP boosted its stake in Pediatrix Medical Group by 12.8% during the second quarter. Brandes Investment Partners LP now owns 735,068 shares of the company's stock worth $5,438,000 after buying an additional 83,588 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in Pediatrix Medical Group by 14.1% during the third quarter. Principal Financial Group Inc. now owns 513,618 shares of the company's stock worth $5,953,000 after buying an additional 63,581 shares during the last quarter. 97.71% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now owns 135,810 shares in the company, valued at approximately $2,172,960. This represents a 5.63 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the transaction, the director now owns 138,683 shares in the company, valued at approximately $2,128,784.05. The trade was a 16.60 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MD. Deutsche Bank Aktiengesellschaft upped their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a "hold" rating in a research note on Monday, November 4th. Truist Financial upped their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a "hold" rating in a research note on Monday, November 4th. UBS Group upped their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. StockNews.com downgraded Pediatrix Medical Group from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Finally, Jefferies Financial Group boosted their price objective on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $16.10.

Pediatrix Medical Group Trading Down 0.6 %

Shares of MD stock traded down $0.09 on Thursday, hitting $14.80. The stock had a trading volume of 113,456 shares, compared to its average volume of 857,569. The company's 50 day moving average price is $13.60 and its 200-day moving average price is $10.41. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. Pediatrix Medical Group, Inc. has a 1 year low of $6.62 and a 1 year high of $16.41. The firm has a market capitalization of $1.27 billion, a P/E ratio of -4.87, a P/E/G ratio of 2.10 and a beta of 1.57.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The company had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. During the same quarter in the prior year, the business earned $0.29 EPS. Pediatrix Medical Group's revenue was up .9% on a year-over-year basis. Analysts anticipate that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.